In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Pharmaceutical Science to Improve the Human Condition

Edited by Edited by Annals of the New York Academy of Sciences editorial staff
Pharmaceutical Science to Improve the Human Condition

Published: July 2013

Volume 1291

Learn More

The Prix Galien USA recognizes excellence in biopharmaceutical research and development that can make significant improvements in the human condition. This Annals volume presents the scientific achievements by winners and finalists of the 2012 Prix Galien USA. Contributions include scholarly summaries from biopharmaceutical industry leaders (GlaxoSmithKline, MethylGene, Bristol-Myers Squibb, Novartis, Optimer Pharmaceuticals, Janssen, Bayer, Merck, UCB Pharma, Medtronic, and Novocure) on pharmaceutical advances in the treatment of a wide range of diseases including advanced melanoma, C. difficile–associated diarrhea, partial-onset seizures, chronic hepatitis C infection, recurrent glioblastoma, and thrombosis-mediated conditions, as well as advances in transcatheter valve technology and ventricular assist devices.